A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of PTC518 in Participants With Huntington's Disease
Latest Information Update: 20 Sep 2024
At a glance
- Drugs Votoplam (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors PTC Therapeutics
Most Recent Events
- 15 Feb 2024 New trial record